Multiple companies, including Biogen, Royalty Pharma with Litifilimab, Biogen in collaboration with UCB for Dapirolizumab pegol, Idorsia Pharmaceuticals partnering with Viatris for Cenerimod, Novartis developing Ianalumab and YTB3231, and Kyowa Kirin working on KK-4277, among others, are progressing with late, mid, and early-stage drugs, demonstrating potential efficacy in systemic conditions.